New Delhi:
The Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, on Monday announced sturdy benefits of the study on neutralizing the activity of sera from folks vaccinated with Sputnik V vaccine against new variants of SARS-CoV-2.
The enterprise mentioned, vaccination with Sputnik V has created protective neutralizing titers against new variants, like Alpha B.1.1.7 (1st identified in the UK), Beta B.1.351 (1st identified in South Africa), Gamma P.1 (1st identified in Brazil), Delta B.1.617.2 and B.1.617.3 (1st identified in India) and Moscow endemic variants B.1.1.141 and B.1.1.317 with mutations in the receptor-binding domain (RBD).
“The methodology was based on the assessment of virus-neutralizing activity (VNA) using the live virus, which provides the most reliable data and is the gold standard. It compared neutralizing activity of Sputnik V induced sera to the internationally relevant variants with the neutralizing activity to the ancestral B.1.1.1 variant. The sera were obtained from individuals after vaccination with two doses of Sputnik V,” the enterprise mentioned.
The study methodology was described in the investigation paper published in a major international journal on July 12, 2021.
“Sputnik V pioneered the vaccine cocktail approach with two shots. The tests conducted by the Gamaleya Center have demonstrated the validity of this approach as the virus-neutralizing activity against new strains, which are more dangerous and infectious, remains higher than that of many other vaccines. RDIF will continue supporting further studies of the efficacy of Sputnik V against new strains while also analyzing opportunities to partner with other leading vaccine producers for developing vaccine cocktails using the first shot of Sputnik V,” mentioned Kirill Dmitriev, CEO of the RDIF.
Virus neutralizing activity assay is not straight associated to the effectiveness of a vaccine.
“The data confirms that Sputnik V remains protective against newly detected variants. Notably, Sputnik V demonstrated significantly less of a reduction in its virus-neutralizing activity against a number of variants compared to data from other vaccine producers, which had earlier confirmed the efficacy of their vaccines against new variants of coronavirus,” as per the enterprise.
The Gamaleya Center and RDIF are also studying new possibilities to create vaccine cocktails jointly with other major COVID vaccine producers applying the 1st element of Sputnik V.
“Our studies have demonstrated strong results of Sputnik V against new variants of SARS-CoV-2. We receive more evidence of the ability of coronavirus to transform and mutate across the globe. Today Sputnik V is one of the most effective vaccines against both original and new variants of coronavirus thanks to its unique approach of using two different adenoviral vectors as a delivery mechanism,” mentioned Alexander Gintsburg, Director of the Gamaleya National Research Center of Epidemiology and Microbiology.
Sputnik V has been registered in 67 nations globally with a total population of more than 3.5 billion folks.
According to the enterprise, the true-world information obtained throughout the vaccination of the population in a quantity of nations, like Mexico, Argentina, Serbia, Bahrain, Hungary, San-Marino, UAE and other individuals, demonstrates that Sputnik V is one of the safest and most efficient vaccines against coronavirus.